- Article
- Source: Campus Sanofi
- Sep 16, 2025
Btk Enzyme
The Bruton’s Tyrosine Kinase (BTK) enzyme is a promising new focus of research1,2
BTK is vital for activation of both B cells and microglia in MS.1,2
- In B cells, BTK promotes proliferation, antibody production, and cytokine secretion1,2
- When activated, BTK can shift microglia from their homeostatic to their disease-associated state1,2
- BTK is highly expressed in microglia within lesion tissue in patients with SPMS1,2
Modulation of BTK may down regulate inflammation 2,4
For more information about Acute and Smoldering Inflammation, click on this link:
BTK=Bruton's Tyrosine Kinase; IL=interleukin; MS=multiple sclerosis; NF-kb=Nuclear factor kappa B; SPMS=secondary progressive multiple sclerosis;TNF=tumor necrosis factor.
- Frisch ES, Pretzsch R, Weber MS. A milestone in multiple sclerosis therapy: monoclonal antibodies against CD20_yet progress continues. Neurotherapeutics. 2021;18(3):1602-1622.
- Keaney J, Gasser J, Gillet G, Scholz D, Kadiu I. Inhibition of Bruton's tyrosine kinase modulates microglial phagocytosis: therapeutic implications for Alzheimer's disease. J Neuroimmune Pharmacol. 2019;14(3):448-461.
- Häusser-Kinzel S, Weber MS. The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders. Front Immunol. 2019;10:201. doi:10.3389/fimmu.2019.00201
- Hendriks RW. Drug discovery: new BTK inhibitor holds promise. Nat Chem Biol. 2011;7(1):4-5.
MAT-KW-2500337/v1/Sept2025